{"id":"W2903308035","doi":"10.1016/s0140-6736(18)32984-2","title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":726,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Brentuximab vedotin; Medicine; Chemotherapy; Oncology; Internal medicine; Lymphoma; Peripheral; CD30; Peripheral T-cell lymphoma; Double blind; Phases of clinical research; Immunology; Pathology; T cell; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001881667,0.002066009,0.003462487,0.0003827687,0.0003457967,0.001307365,0.0009392854,0.00185584,0.006326919],"category_scores_gemma":[0.001529084,0.000736364,0.002336612,0.0004570549,0.001626891,0.001798795,0.0005925761,0.003502285,0.001218684],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007838069,"about_ca_system_score_gemma":0.000776579,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009024608,"about_ca_topic_score_gemma":0.001770516,"domain_scores_codex":[0.9992213,0.0004198037,0.00003659231,0.0001421571,0.00004340756,0.0001367659],"domain_scores_gemma":[0.9993136,0.0002017321,0.0001465476,0.00006633667,0.00003603781,0.0002357476],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9817292,0.001345543,0.0002578441,0.0008506948,0.001026071,0.0000352855,0.00004321612,0.0003334417,0.001474085,0.0001472599,0.0008351639,0.01192221],"study_design_scores_gemma":[0.9809459,0.0171436,0.0006580152,0.00003232679,0.0002568731,0.00002481994,0.00001281064,0.0001569026,0.0001314646,0.0001645271,0.0004629549,0.000009685658],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9711199,0.01552716,0.00162192,0.001550225,0.00149924,0.003398006,0.001693633,0.0003075758,0.003282188],"genre_scores_gemma":[0.9775591,0.006442314,0.002372896,0.00213564,0.0005180586,0.003855738,0.001541248,0.00006297658,0.005512006],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006326919,"threshold_uncertainty_score":0.02116561,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03926279559710762,"score_gpt":0.3382484745491339,"score_spread":0.2989856789520263,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}